QST Consultations Selects Merge's eClinical OS(TM) Clinical Trial Platform
October 10 2013 - 7:00AM
Merge Healthcare Incorporated (Nasdaq:MRGE), a leading provider of
clinical systems and innovations that seek to transform healthcare,
today announced that QST Consultations, Ltd. has selected Merge's
eClinical OS™ solution as its preferred clinical trial platform to
support Phases I, II and III and Post-Marketing studies on a global
basis.
"We currently work with a range of sponsors that extend from
small start-up organizations to well-established leaders in the
pharmaceutical industry. We have developed significant therapeutic
expertise in several key areas such as dermatology, ophthalmology,
pulmonary, allergy, pain management, women's health, obesity, and
several others that include wide-ranging support for dozens of
approved submissions," explained Nancy Fitzgerald, CEO of QST
Consultations. "Finding one system that is flexible enough to work
for all types of studies was very important to us."
"We initially looked at eClinical OS because it is a single
platform with all the study support capabilities we may need for a
particular study, such as EDC, IWR/IVR, endpoint adjudication, or
randomization," Fitzgerald continued. "Additionally, we were
pleased with the option to choose self-service or partnering with
Merge for study build services. With the intuitive study builder
and built-in study templates, we can create studies quickly without
having to outsource to a third party. This not only means we can
improve timelines for our clients, but we can also better control
costs, resulting in more competitive bids."
"With nearly 40 years experience providing clinical study
consultation to the pharmaceutical and medical device industries,
QST Consultations has used many different technologies to help
clients manage and run studies," said Zaher El-Assi, President of
Merge eClinical. "We're very pleased with their selection of Merge
eClinical OS as a preferred solution and with their dedication in
becoming a Merge certified expert-level builder. By implementing a
single platform, they can spend less time and resources integrating
numerous technologies for each study, and more time directly
supporting the needs of their clients."
Merge eClinical OS has the flexibility to support trials in any
stage, and captures any type of data, from any source, over any
modality. Users benefit from the convenience of one operating
platform with countless critical tools that can be mixed and
matched to fit the needs of each trial environment.
About Merge Healthcare
Merge is a leading provider of clinical systems and innovations
that seek to transform healthcare. Merge's enterprise and
cloud-based solutions for image intensive specialties provide
access to any image, anywhere, any time. Merge also provides health
stations, clinical trials software and other health data and
analytics solutions that engage consumers in their personal health.
With solutions that are used by providers and consumers and include
more than 20 years of innovation, Merge is helping to reduce costs
and improve the quality of healthcare worldwide. For more
information, visit merge.com.
About QST Consultations, Ltd.
QST Consultations, Ltd. was founded in 1974 and is an
independent consulting firm for the medical device and
pharmaceutical industries. QST specializes in clinical study
design, protocol development, case report form design, data
management, biostatistical analysis, report writing, and
statistical consultation. The company's involvement includes many
successful Phase I-III and Post-Marketing clinical trials designed
to support 510(k), PMA, ANDA, and NDA submissions, along with
ongoing marketing activities. For more information, visit
qstconsultations.com.
Cautionary Notice Regarding Forward-Looking
Statements
The matters discussed in this news release may include
forward-looking statements, which could involve a number of risks
and uncertainties. When used in this press release, the words
"will," "believes," "intends," "anticipates," "expects" and similar
expressions are intended to identify forward-looking statements.
Actual results could differ materially from those expressed in, or
implied by, such forward-looking statements. Except as expressly
required by the federal securities laws, the Company undertakes no
obligation to update such factors or to publicly announce the
results of any of the forward-looking statements.
CONTACT: Media Contacts:
Jennifer Jawor
Director, Corporate Marketing
312.565.6825
jennifer.jawor@merge.com
Mirage Energy (PK) (USOTC:MRGE)
Historical Stock Chart
From Jun 2024 to Jul 2024
Mirage Energy (PK) (USOTC:MRGE)
Historical Stock Chart
From Jul 2023 to Jul 2024